Therapeutic Drug Development
Argenica is developing a neuroprotective peptide drug called ARG-007 to be used in the treatment of stroke
Argenica Drug Development Pathway
The drug development pathway is tightly regulated and involves the sequential demonstration of both safety and efficacy of the compounds. ARG-007 will comply with the appropriate International Standards and Guidelines. Additionally, Argenica follows the Stroke Treatment Academic Industry Roundtable (STAIR) priorities that were developed to address the past translational failings in neuroprotective therapy development.
Argenica intends to develop ARG-007 through the typical drug development pathways in applications where neuroprotection provides enhanced benefits
Efficacy has been demonstrated in many preclinical models of stroke and other brain injuries. Preliminary distribution data indicates ARG-007 is mainly excreted by the kidneys. No immunogenicity and no toxicity has been observed to date with the delivery of Argenica.
Argenica is currently completing the required safety and related pharmaco- and toxico-kinetic studies needed for “first in human” studies and anticipates entering Phase 1 clinical trials to assess the safety of ARG-007 in healthy subjects in the second half of 2021.